The group's principle activity is to develop products that are intended to substantially improve the symptoms of terrible, debilitating diseases of the brain and eyes, and for the first time ever slow, halt or possibly reverse their progression. The group also provides research programs investigating therapies for other neurodegenerative disorders. The group operates from United States.
